This trial has been completed.

Condition balanced chromosomal translocation
Sponsor Reproductive Medicine Associates of New Jersey
Start date June 2014
End date December 2015
Trial size 11 participants
Trial identifier NCT02178865, RMA-2014-01


The purpose of this study is to assess the accuracy of predicting the normal or carrier status of human embryos resulting from in vitro-fertilization (IVF) from patients carrying a balanced translocation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective other
balanced translocation carriers who have undergone IVF

Primary Outcomes

Proportion of correct predictions of normal vs. balanced ploidy status as compared to conventional karyotype
time frame: up to 12 months once pregnant

Eligibility Criteria

All participants at least 7 years old.

Inclusion Criteria: - patients with balanced translocations who have undergone IVF Exclusion Criteria: - those who do not wish to know their child(s) karyotype

Additional Information

Official title Evaluation of the Accuracy of Predicting Normal or Carrier Status in Euploid Embryos Produced by Patients With Balanced Translocations
Principal investigator Richard T Scott, MD, HCLD
Description This study aims to evaluate the validity of using informative SNPs to distinguish balanced from normal embryos. This will involve acquiring material from families to set phase for informative SNPs, evaluation of existing and new embryo SNP array data, and follow up analysis of children born after applying the procedure.
Trial information was received from ClinicalTrials.gov and was last updated in March 2017.
Information provided to ClinicalTrials.gov by Reproductive Medicine Associates of New Jersey.